AU2007206750A1 - Enrichment of cells - Google Patents
Enrichment of cells Download PDFInfo
- Publication number
- AU2007206750A1 AU2007206750A1 AU2007206750A AU2007206750A AU2007206750A1 AU 2007206750 A1 AU2007206750 A1 AU 2007206750A1 AU 2007206750 A AU2007206750 A AU 2007206750A AU 2007206750 A AU2007206750 A AU 2007206750A AU 2007206750 A1 AU2007206750 A1 AU 2007206750A1
- Authority
- AU
- Australia
- Prior art keywords
- mscs
- cells
- collagenase
- bone
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 319
- 210000004027 cell Anatomy 0.000 claims description 283
- 238000000034 method Methods 0.000 claims description 104
- 210000001185 bone marrow Anatomy 0.000 claims description 89
- 102000029816 Collagenase Human genes 0.000 claims description 74
- 108060005980 Collagenase Proteins 0.000 claims description 74
- 229960002424 collagenase Drugs 0.000 claims description 71
- 210000001519 tissue Anatomy 0.000 claims description 67
- 210000000988 bone and bone Anatomy 0.000 claims description 52
- 210000000577 adipose tissue Anatomy 0.000 claims description 43
- 238000011282 treatment Methods 0.000 claims description 36
- 230000008439 repair process Effects 0.000 claims description 28
- 201000008482 osteoarthritis Diseases 0.000 claims description 22
- 210000001258 synovial membrane Anatomy 0.000 claims description 22
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims description 20
- 238000002659 cell therapy Methods 0.000 claims description 18
- 210000000845 cartilage Anatomy 0.000 claims description 17
- 230000029087 digestion Effects 0.000 claims description 17
- 238000002560 therapeutic procedure Methods 0.000 claims description 14
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 13
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 13
- 210000002744 extracellular matrix Anatomy 0.000 claims description 13
- 239000000872 buffer Substances 0.000 claims description 11
- 208000001132 Osteoporosis Diseases 0.000 claims description 10
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 9
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- 238000007667 floating Methods 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 8
- 230000008901 benefit Effects 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 238000007388 punch biopsy Methods 0.000 claims description 6
- 108010003272 Hyaluronate lyase Proteins 0.000 claims description 5
- 102000001974 Hyaluronidases Human genes 0.000 claims description 5
- 229960002773 hyaluronidase Drugs 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 230000008929 regeneration Effects 0.000 claims description 4
- 238000011069 regeneration method Methods 0.000 claims description 4
- 239000011324 bead Substances 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 210000002435 tendon Anatomy 0.000 claims description 3
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 238000001415 gene therapy Methods 0.000 claims description 2
- 208000024908 graft versus host disease Diseases 0.000 claims description 2
- 230000000302 ischemic effect Effects 0.000 claims description 2
- 210000003041 ligament Anatomy 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 230000005499 meniscus Effects 0.000 claims description 2
- 210000004165 myocardium Anatomy 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 210000004197 pelvis Anatomy 0.000 claims description 2
- 210000002027 skeletal muscle Anatomy 0.000 claims description 2
- 208000020431 spinal cord injury Diseases 0.000 claims description 2
- 210000001562 sternum Anatomy 0.000 claims description 2
- 210000000689 upper leg Anatomy 0.000 claims description 2
- 230000002792 vascular Effects 0.000 claims description 2
- 231100000216 vascular lesion Toxicity 0.000 claims description 2
- 238000001574 biopsy Methods 0.000 description 33
- 210000003668 pericyte Anatomy 0.000 description 26
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 21
- 238000001727 in vivo Methods 0.000 description 21
- 239000002953 phosphate buffered saline Substances 0.000 description 21
- 210000002945 adventitial reticular cell Anatomy 0.000 description 19
- 210000002950 fibroblast Anatomy 0.000 description 18
- 239000011325 microbead Substances 0.000 description 17
- 210000001789 adipocyte Anatomy 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 210000000130 stem cell Anatomy 0.000 description 15
- 210000005222 synovial tissue Anatomy 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 13
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 13
- 230000004069 differentiation Effects 0.000 description 11
- 239000008188 pellet Substances 0.000 description 11
- 238000000684 flow cytometry Methods 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 10
- 230000002188 osteogenic effect Effects 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 230000002648 chondrogenic effect Effects 0.000 description 9
- 230000007547 defect Effects 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 230000002255 enzymatic effect Effects 0.000 description 9
- 229940088598 enzyme Drugs 0.000 description 9
- 239000003550 marker Substances 0.000 description 9
- 229920002683 Glycosaminoglycan Polymers 0.000 description 8
- 230000003021 clonogenic effect Effects 0.000 description 8
- 230000006862 enzymatic digestion Effects 0.000 description 8
- 238000002955 isolation Methods 0.000 description 8
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 208000014674 injury Diseases 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 210000005087 mononuclear cell Anatomy 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 238000012876 topography Methods 0.000 description 7
- 238000002405 diagnostic procedure Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000003102 growth factor Substances 0.000 description 6
- 210000000963 osteoblast Anatomy 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 102100022464 5'-nucleotidase Human genes 0.000 description 5
- 102100022749 Aminopeptidase N Human genes 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 5
- 102000003729 Neprilysin Human genes 0.000 description 5
- 108090000028 Neprilysin Proteins 0.000 description 5
- 230000005856 abnormality Effects 0.000 description 5
- 238000010420 art technique Methods 0.000 description 5
- 239000013553 cell monolayer Substances 0.000 description 5
- 210000002889 endothelial cell Anatomy 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 5
- 230000002062 proliferating effect Effects 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 210000002536 stromal cell Anatomy 0.000 description 5
- 208000010392 Bone Fractures Diseases 0.000 description 4
- 201000005569 Gout Diseases 0.000 description 4
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 4
- 102100025323 Integrin alpha-1 Human genes 0.000 description 4
- 206010031243 Osteogenesis imperfecta Diseases 0.000 description 4
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 4
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 4
- 102100033725 Tumor necrosis factor receptor superfamily member 16 Human genes 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 210000001612 chondrocyte Anatomy 0.000 description 4
- 210000004748 cultured cell Anatomy 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 210000000229 preadipocyte Anatomy 0.000 description 4
- 210000004872 soft tissue Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000008736 traumatic injury Effects 0.000 description 4
- 102100023126 Cell surface glycoprotein MUC18 Human genes 0.000 description 3
- 206010017076 Fracture Diseases 0.000 description 3
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 description 3
- 101000623903 Homo sapiens Cell surface glycoprotein MUC18 Proteins 0.000 description 3
- 102000000704 Interleukin-7 Human genes 0.000 description 3
- 108010002586 Interleukin-7 Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 3
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 3
- 230000002293 adipogenic effect Effects 0.000 description 3
- 238000007470 bone biopsy Methods 0.000 description 3
- 208000015322 bone marrow disease Diseases 0.000 description 3
- 230000022159 cartilage development Effects 0.000 description 3
- 230000032823 cell division Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 210000000704 endosteal cell Anatomy 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000003306 harvesting Methods 0.000 description 3
- 210000001624 hip Anatomy 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000002894 multi-fate stem cell Anatomy 0.000 description 3
- 210000004409 osteocyte Anatomy 0.000 description 3
- 230000009758 senescence Effects 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 102100024210 CD166 antigen Human genes 0.000 description 2
- 102100025222 CD63 antigen Human genes 0.000 description 2
- 102100027221 CD81 antigen Human genes 0.000 description 2
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- 208000032170 Congenital Abnormalities Diseases 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 102100029722 Ectonucleoside triphosphate diphosphohydrolase 1 Human genes 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 206010020100 Hip fracture Diseases 0.000 description 2
- 101000934368 Homo sapiens CD63 antigen Proteins 0.000 description 2
- 101000914479 Homo sapiens CD81 antigen Proteins 0.000 description 2
- 101001012447 Homo sapiens Ectonucleoside triphosphate diphosphohydrolase 1 Proteins 0.000 description 2
- 101001078158 Homo sapiens Integrin alpha-1 Proteins 0.000 description 2
- 108010041341 Integrin alpha1 Proteins 0.000 description 2
- 108010055795 Integrin alpha1beta1 Proteins 0.000 description 2
- 102100023430 Junctional adhesion molecule B Human genes 0.000 description 2
- MIJPAVRNWPDMOR-ZAFYKAAXSA-N L-ascorbic acid 2-phosphate Chemical compound OC[C@H](O)[C@H]1OC(=O)C(OP(O)(O)=O)=C1O MIJPAVRNWPDMOR-ZAFYKAAXSA-N 0.000 description 2
- 102100021747 Leukemia inhibitory factor receptor Human genes 0.000 description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
- 102000016611 Proteoglycans Human genes 0.000 description 2
- 108010067787 Proteoglycans Proteins 0.000 description 2
- 206010062164 Seronegative arthritis Diseases 0.000 description 2
- 101150052863 THY1 gene Proteins 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000009815 adipogenic differentiation Effects 0.000 description 2
- RGCKGOZRHPZPFP-UHFFFAOYSA-N alizarin Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC=C3C(=O)C2=C1 RGCKGOZRHPZPFP-UHFFFAOYSA-N 0.000 description 2
- 238000011882 arthroplasty Methods 0.000 description 2
- 210000001188 articular cartilage Anatomy 0.000 description 2
- 238000011130 autologous cell therapy Methods 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 230000010307 cell transformation Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000009816 chondrogenic differentiation Effects 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 230000000626 neurodegenerative effect Effects 0.000 description 2
- 230000011164 ossification Effects 0.000 description 2
- 230000009818 osteogenic differentiation Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 210000001778 pluripotent stem cell Anatomy 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000010079 rubber tapping Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 210000000242 supportive cell Anatomy 0.000 description 2
- 238000011285 therapeutic regimen Methods 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 210000003954 umbilical cord Anatomy 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 108010075348 Activated-Leukocyte Cell Adhesion Molecule Proteins 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000017234 Bone cyst Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 102100035716 Glycophorin-A Human genes 0.000 description 1
- 108091005250 Glycophorins Proteins 0.000 description 1
- 101001050320 Homo sapiens Junctional adhesion molecule B Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 206010031264 Osteonecrosis Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 108010049264 Teriparatide Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000011759 adipose tissue development Effects 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 230000010478 bone regeneration Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000003321 cartilage cell Anatomy 0.000 description 1
- 230000003848 cartilage regeneration Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 208000017568 chondrodysplasia Diseases 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 210000001608 connective tissue cell Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 229940077085 diagnostic agent for diabetes testing Drugs 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N glycerol 1-phosphate Chemical compound OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 210000004524 haematopoietic cell Anatomy 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 108040006861 interleukin-7 receptor activity proteins Proteins 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000004523 ligament cell Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 210000001872 metatarsal bone Anatomy 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 206010028537 myelofibrosis Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229960002378 oftasceine Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000278 osteoconductive effect Effects 0.000 description 1
- 230000002138 osteoinductive effect Effects 0.000 description 1
- 208000002865 osteopetrosis Diseases 0.000 description 1
- 230000001009 osteoporotic effect Effects 0.000 description 1
- 230000009340 pathogen transmission Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 210000004786 perivascular cell Anatomy 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000012342 propidium iodide staining Methods 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000002278 reconstructive surgery Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- YEENEYXBHNNNGV-XEHWZWQGSA-M sodium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate;(2r,3r,4s,5s,6r)-2-[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I.O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YEENEYXBHNNNGV-XEHWZWQGSA-M 0.000 description 1
- 208000028528 solitary bone cyst Diseases 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000009168 stem cell therapy Methods 0.000 description 1
- 238000009580 stem-cell therapy Methods 0.000 description 1
- 229940079488 strontium ranelate Drugs 0.000 description 1
- XXUZFRDUEGQHOV-UHFFFAOYSA-J strontium ranelate Chemical compound [Sr+2].[Sr+2].[O-]C(=O)CN(CC([O-])=O)C=1SC(C([O-])=O)=C(CC([O-])=O)C=1C#N XXUZFRDUEGQHOV-UHFFFAOYSA-J 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 description 1
- 229960005460 teriparatide Drugs 0.000 description 1
- 229950003937 tolonium Drugs 0.000 description 1
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
- 238000011541 total hip replacement Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 238000007631 vascular surgery Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 108010047303 von Willebrand Factor Proteins 0.000 description 1
- 102100036537 von Willebrand factor Human genes 0.000 description 1
- 229960001134 von willebrand factor Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0668—Mesenchymal stem cells from other natural sources
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0600972.4 | 2006-01-18 | ||
| GBGB0600972.4A GB0600972D0 (en) | 2006-01-18 | 2006-01-18 | Enrichment of cells |
| PCT/GB2007/000107 WO2007083093A1 (en) | 2006-01-18 | 2007-01-17 | Enrichment of cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2007206750A1 true AU2007206750A1 (en) | 2007-07-26 |
Family
ID=36010490
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2007206750A Abandoned AU2007206750A1 (en) | 2006-01-18 | 2007-01-17 | Enrichment of cells |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20100260721A1 (enExample) |
| EP (1) | EP1979471A1 (enExample) |
| JP (1) | JP2009523438A (enExample) |
| CN (1) | CN101400786A (enExample) |
| AU (1) | AU2007206750A1 (enExample) |
| GB (1) | GB0600972D0 (enExample) |
| WO (1) | WO2007083093A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2010109698A (ru) * | 2007-09-19 | 2011-09-27 | Плуристем Лтд. (Il) | Адгезивные клетки жировой ткани или плаценты и их использование в лечебных целях |
| JP5645197B2 (ja) * | 2009-06-23 | 2014-12-24 | 学校法人日本大学 | 幹細胞の未分化状態を維持する新規方法 |
| US9169464B2 (en) | 2009-10-16 | 2015-10-27 | Rutgers, The State University Of New Jersey | Closed system separation of adherent bone marrow stem cells for regenerative medicine applications |
| SG10201408187XA (en) * | 2009-12-22 | 2015-01-29 | Agency Science Tech & Res | Treatment of Bone Fracture |
| EP2751256A4 (en) * | 2011-08-29 | 2015-01-28 | Safeguard Cell Technology Inc | ISOLATION AND THERAPEUTIC USE OF PERIVASCULAR MEDICINAL CELLS |
| AU2012307086B2 (en) * | 2011-09-09 | 2016-05-26 | Mesoblast, Inc. | Methods for increasing osteoblastic function |
| CN103266081B (zh) * | 2012-01-21 | 2015-05-13 | 中国人民解放军军事医学科学院附属医院 | 从脐带中分离培养间充质干细胞的高效方法 |
| EP3030279B1 (en) * | 2013-08-06 | 2020-11-04 | Regenexx, LLC | Bone marrow adipose portion isolation device and methods |
| EP2998392A1 (en) * | 2014-09-16 | 2016-03-23 | The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin | A population of cells for use in single-stage cell-based cartilage regeneration |
| TWI566774B (zh) | 2014-10-06 | 2017-01-21 | 佛教慈濟醫療財團法人花蓮慈濟醫院 | 治療關節疾病的組成物及其方法 |
| US10342830B2 (en) | 2015-01-05 | 2019-07-09 | Gary M. Petrucci | Methods and materials for treating lung disorders |
| US20160193254A1 (en) * | 2015-01-05 | 2016-07-07 | Gary M. Petrucci | Methods and materials for treating arthritis |
| WO2017136557A1 (en) | 2016-02-05 | 2017-08-10 | Petrucci Gary M | Methods and materials for treating nerve injuries and neurological disorders |
| US20180059109A1 (en) * | 2016-08-31 | 2018-03-01 | Meridigen Biotech Co., Ltd. | Method of distinguishing mesenchymal stem cells and method of determining purity of mesenchymal stem cells |
| US11613733B2 (en) | 2017-05-12 | 2023-03-28 | Medical & Biological Laboratories Co., Ltd. | Method for purifying mesenchymal stem cells to improve transplantation efficiency |
| US10478531B2 (en) | 2017-06-22 | 2019-11-19 | Gary M. Petrucci | Methods and materials for treating blood vessels |
| US10251917B1 (en) | 2017-09-19 | 2019-04-09 | Gary M. Petrucci | Methods and materials for treating tumors |
| US11285177B2 (en) | 2018-01-03 | 2022-03-29 | Globus Medical, Inc. | Allografts containing viable cells and methods thereof |
| US12391924B2 (en) | 2019-02-08 | 2025-08-19 | Regrow Biosciences Private Limited | Method for mesenchymal stem cell isolation and osteoblast differentiation |
| US11697799B2 (en) | 2019-04-15 | 2023-07-11 | Ossium Health, Inc. | System and method for extraction and cryopreservation of bone marrow |
| EP4181675A4 (en) | 2020-07-18 | 2024-04-24 | Ossium Health, Inc. | PERMEATION OF WHOLE VERTEBRATE BODIES WITH A CRYOPRETECTIVE AGENT USING VACUUM-ASSISTED DIFFUSION |
| CN116583594B (zh) | 2020-10-14 | 2025-05-23 | 奥瑟姆健康公司 | 用于骨髓的提取和低温保藏的系统和方法 |
| WO2022133282A1 (en) | 2020-12-18 | 2022-06-23 | Ossium Health, Inc. | Methods of cell therapies |
| KR102858598B1 (ko) | 2025-01-16 | 2025-09-10 | 신종인 | 콜라게나제를 이용한 지방세포 이식용 조성물의 제조방법 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5226914A (en) * | 1990-11-16 | 1993-07-13 | Caplan Arnold I | Method for treating connective tissue disorders |
| US5811094A (en) * | 1990-11-16 | 1998-09-22 | Osiris Therapeutics, Inc. | Connective tissue regeneration using human mesenchymal stem cell preparations |
| US5486359A (en) * | 1990-11-16 | 1996-01-23 | Osiris Therapeutics, Inc. | Human mesenchymal stem cells |
| US6653134B2 (en) * | 1995-03-28 | 2003-11-25 | Cp Hahnemann University | Isolated stromal cells for use in the treatment of diseases of the central nervous system |
| US6482231B1 (en) * | 1995-11-20 | 2002-11-19 | Giovanni Abatangelo | Biological material for the repair of connective tissue defects comprising mesenchymal stem cells and hyaluronic acid derivative |
| CA2251983C (en) * | 1996-04-19 | 2003-12-16 | Sudhakar Kadiyala | Regeneration and augmentation of bone using mesenchymal stem cells |
| US6835377B2 (en) * | 1998-05-13 | 2004-12-28 | Osiris Therapeutics, Inc. | Osteoarthritis cartilage regeneration |
| US6893900B1 (en) * | 1998-06-24 | 2005-05-17 | Amkor Technology, Inc. | Method of making an integrated circuit package |
| US7670628B2 (en) * | 1999-07-07 | 2010-03-02 | Angioblast Systems, Inc. | Mesenchymal precursor cell |
| AU5723601A (en) * | 2000-04-25 | 2001-11-07 | Osiris Therapeutics Inc | Joint repair using mesenchymal stem cells |
| US20030211602A1 (en) * | 2000-04-28 | 2003-11-13 | Anthony Atala | Isolation of mesenchymal stem cells and use thereof |
| US20030103947A1 (en) * | 2001-02-23 | 2003-06-05 | Urlich Noth | In vitro engineered cartilage constructs produced by coating biodegradable polymer with human mesenchymal stem cells |
| AU2003273574A1 (en) * | 2002-05-31 | 2003-12-19 | Osiris Therapeutics, Inc. | Intraperitoneal delivery of genetically engineered mesenchymal stem cells |
| EP1641915B1 (en) * | 2003-06-27 | 2016-07-27 | DePuy Synthes Products, Inc. | Repair and regeneration of ocular tissue using postpartum-derived cells |
-
2006
- 2006-01-18 GB GBGB0600972.4A patent/GB0600972D0/en not_active Ceased
-
2007
- 2007-01-17 US US12/223,056 patent/US20100260721A1/en not_active Abandoned
- 2007-01-17 EP EP07700381A patent/EP1979471A1/en not_active Withdrawn
- 2007-01-17 JP JP2008550832A patent/JP2009523438A/ja active Pending
- 2007-01-17 AU AU2007206750A patent/AU2007206750A1/en not_active Abandoned
- 2007-01-17 WO PCT/GB2007/000107 patent/WO2007083093A1/en not_active Ceased
- 2007-01-17 CN CNA2007800087785A patent/CN101400786A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20100260721A1 (en) | 2010-10-14 |
| GB0600972D0 (en) | 2006-03-01 |
| WO2007083093A1 (en) | 2007-07-26 |
| EP1979471A1 (en) | 2008-10-15 |
| JP2009523438A (ja) | 2009-06-25 |
| CN101400786A (zh) | 2009-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20100260721A1 (en) | Enrichment of Cells | |
| US11926848B2 (en) | Stromal stem cells | |
| US8440440B2 (en) | Ultrasonic cavitation derived stromal or mesenchymal vascular extracts and cells derived therefrom obtained from adipose tissue and use thereof | |
| EP1845154A1 (en) | Multipotent stem cells derived from placenta tissue and cellular therapeutic agents comprising the same | |
| Cuthbert et al. | Examining the feasibility of clinical grade CD271+ enrichment of mesenchymal stromal cells for bone regeneration | |
| Cox et al. | High abundance of CD271+ multipotential stromal cells (MSCs) in intramedullary cavities of long bones | |
| EP3578641A1 (en) | Method for preparing dental pulp stem cells from cells derived from dental pulp tissue | |
| Otto et al. | Proximal humerus and ilium are reliable sources of bone marrow aspirates for biologic augmentation during arthroscopic surgery | |
| US11578306B2 (en) | Methods for propagating mesenchymal stem cells (MSC) for use in transplantation | |
| JP7064254B2 (ja) | ヒト臍帯から幹細胞を分離する方法 | |
| US11613733B2 (en) | Method for purifying mesenchymal stem cells to improve transplantation efficiency | |
| CN102864123B (zh) | 一种外周血间充质干细胞的获得方法及其应用 | |
| da Rocha et al. | A new option for bone regeneration: a rapid methodology for cellularization of allograft with human bone marrow stromal cells with in vivo bone-forming potential | |
| Talakoob et al. | Capability of cartilage extract to in vitro differentiation of rat mesenchymal stem cells (MSCs) to chondrocyte lineage | |
| Li et al. | Technique for Isolation and Culture of Rat Jaw Bone Marrow Mesenchymal Stem Cells | |
| CN104357385A (zh) | 一种半月板组织来源的间充质干细胞及其制备方法和鉴定 | |
| CN104357386A (zh) | 一种前交叉韧带残端来源的间充质干细胞的制备方法 | |
| El-Sheshtawy | Isolation and Characterization of Human Dental Pulp Stem Cells and Their In Vitro Dif-ferentiation into Odontoblast and Nerve-Like Cells | |
| Lause | Testing for osteogenic potential of human mesenchymal stem cells | |
| Cuthbert | Exploiting knowledge of mesenchymal stromal cells in vivo for bone disease therapy development | |
| HK1123071B (en) | Isolation of adult multipotential cells by tissue non-specific alkaline phosphatase | |
| HK1123071A1 (en) | Isolation of adult multipotential cells by tissue non-specific alkaline phosphatase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |